ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

aumolertinib

Also written as “Almonertinib”, “Aumolertinib” and “HS-10296”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 4 companies.

Drug pageAumolertinib: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 23, 201815 company-led studies, 8 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Groupits history only85 open or runningphase 3since Nov 23, 2018Nov 28, 2016none ahead
Jiangsu HengRui Medicineits history only43 open or runningphase 3since Sep 12, 2025Apr 2, 2019Jul 30, 2027phase 2 · NCT05503888
EQRx International20 open or runningphase 3since Jun 24, 2022Nov 5, 2021none ahead
Revolution Medicinesits history only10 open or runningphase 1since Jul 13, 2021Jul 13, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of EQRx International only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2020Named aumolertinibINNProposed as its International Nonproprietary Name in WHO's List 124 · before, HS-10296
  2. Nov 5, 2021First study: phase 1 study in Severe Hepatic ImpairmentFirst studyNCT05199610 · 12 enrolled · United States
  3. Jun 24, 2022Phase 3 study in NSCLCNCT05493501 · 8 enrolled · United States

TargetBeta

EGFR →read by rule
“An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 2 EQRx International leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05493501NSCLC · United States3TerminatedAug 31, 20238
NCT05199610Severe Hepatic Impairment · United States1CompletedApr 1, 202312

How it is read

Names in the registry

  • “Almonertinib”, 3 entries
  • “Aumolertinib”, 2 entries
  • “aumolertinib”, 2 entries
  • “HS-10296”, 2 entries
  • “almonertinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.